This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

Needham & Company LLC reaffirmed their hold rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a ...

Vertex Pharmaceuticals (NASDAQ ... Judging by the results, the company may not have a winner on its hands. The candidate is already being considered for approval by regulators at the Food and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...

Vertex Pharmaceuticals shares fell after the company reported mixed results from a study of a treatment for patients with lumbosacral radiculopathy, a neurological disorder that causes back and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...